NDAORALCAPSULEPriority Review
Approved
Nov 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ZARONTIN (ethosuximide) by Pfizer is clinical pharmacology ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. Approved for epilepsy. First approved in 1960.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Zarontin (ethosuximide) is an oral anti-epileptic agent approved in 1960 for the treatment of absence (petit mal) seizures. It works by suppressing the characteristic 3-cycle-per-second spike-and-wave activity associated with absence seizures and raising the seizure threshold in the central nervous system. The drug is administered as an oral capsule and remains a foundational therapy for this specific seizure type.
$0.217MPart D
LOE ApproachingDeclining
As an LOE-approaching product with modest Part D spending ($217K in 2023), this brand faces significant commercial contraction and likely operates with a lean, maintenance-focused team.
Mechanism of Action
CLINICAL PHARMACOLOGY Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…
Pharmacologic Class:
Anti-epileptic Agent
Indications (1)
Career Relevance
Working on Zarontin offers limited career growth and minimal job availability (0 linked positions) due to its LOE-approaching status and narrow patient population. Roles are primarily defensive and operational, focused on managing decline rather than driving innovation or market expansion.
Worked on ZARONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.